AnPac Bio Announces Changes to the Board of Directors
10 November 2022 - 11:30PM
GlobeNewswire Inc.
AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or
the “Company”), a biotechnology company with operations in the
United States and China focused on early cancer screening and
detection, today announced the resignation of Yuyang Cui as (i) the
Co-Chair of the board of directors (the “Board”), and (ii) the
Co-Chief Executive Officer, effective from November 7, 2022, and
the resignation of Jiawen Kang from the position of (i) a director
of the Board, (ii) a member of the audit committee, and (iii) a
member of the nominating and corporate governance committee,
effective from November 4, 2022.
Mr. Haohan Xu, the Co-Chairperson and Co-Chief Executive
Officer of the Company, said, “On behalf of the Board of Directors
and management team, I would like to express our sincere gratitude
to them for all their contributions to the Company.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on
early cancer screening and detection, with 155 issued patents as of
March 31, 2022. With two certified clinical laboratories in China
and one CLIA and CAP accredited clinical laboratory in the United
States, AnPac Bio performs a suite of cancer screening and
detection tests, including CDA (Cancer Differentiation Analysis),
bio-chemical, immunological, and genomics tests. According to a
report by Frost & Sullivan, AnPac Bio ranked first globally in
multi-cancer screening and detection test sample volume
(accumulative to January 2021). AnPac Bio’s CDA technology platform
has been shown in retrospective validation studies to be able to
detect the risk of over 20 different cancer types with high
sensitivity and specificity.
For investor and media inquiries, please
contact:
Company:
Phil Case, Marketing and Investor RelationsPhone:
+1-267-810-6776 (US)Email: phil_case@AnPacbio.com
Safe Harbor Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company’s future financial and operating
performance. The Company has attempted to identify forward-looking
statements by terminologies including “believes,” “estimates,”
“anticipates,” “expects,” “plans,” “projects,” “intends,”
“potential,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal”
“objective,” “assume,” “contemplate,” “continue,” “positioned,”
“forecast,” “likely,” “may,” “could,” “might,” “will,” “should,”
“approximately” or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company’s control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
our ability to comply with Nasdaq Listing Rules, the implementation
of our business model and growth strategies; trends and competition
in the cancer screening and detection market; our expectations
regarding demand for and market acceptance of our cancer screening
and detection tests and our ability to expand our customer base;
our ability to obtain and maintain intellectual property
protections for our CDA technology and our continued research and
development to keep pace with technology developments; our ability
to obtain and maintain regulatory approvals from the NMPA, the FDA
and the relevant U.S. states and have our laboratories certified or
accredited by authorities including the CLIA; our future business
development, financial condition and results of operations and our
ability to obtain financing cost-effectively; potential changes of
government regulations; general economic and business conditions in
China and elsewhere; our ability to hire and maintain key
personnel; our relationship with our major business partners and
customers; and the duration of the coronavirus outbreaks and their
potential adverse impact on the economic conditions and financial
markets and our business and financial performance, such as
resulting from reduced commercial activities due to quarantines and
travel restrictions instituted by China, the U.S. and many other
countries around the world to contain the spread of the virus.
Additionally, all forward-looking statements are subject to the
“Risk Factors” detailed from time to time in the Company’s most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission. Because of these and other
risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these
statements speak only as of the date of this press release and,
except as may be required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to May 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From May 2022 to May 2023